News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
8,013 Results
Type
Article (1969)
Company Profile (3)
Press Release (6041)
Multimedia
Podcasts (17)
Webinars (1)
Section
Business (3232)
Career Advice (22)
Deals (457)
Drug Delivery (5)
Drug Development (1742)
Employer Resources (12)
FDA (230)
Job Trends (314)
News (5097)
Policy (433)
Tag
Academia (42)
Accelerated approval (3)
Adcomms (3)
Alliances (645)
ALS (15)
Alzheimer's disease (375)
Antibody-drug conjugate (ADC) (2)
Approvals (219)
Artificial intelligence (5)
Autoimmune disease (7)
Bankruptcy (3)
Best Places to Work (165)
Biosimilars (11)
Biotechnology (2)
Brain cancer (1)
Breast cancer (2)
Cancer (20)
Cardiovascular disease (8)
Career advice (24)
Career pathing (1)
CAR-T (1)
CDC (1)
Cell therapy (8)
Clinical research (1221)
Collaboration (27)
Compensation (1)
Complete response letters (5)
COVID-19 (44)
CRISPR (1)
C-suite (34)
Cystic fibrosis (1)
Data (67)
Depression (11)
Diabetes (1)
Diagnostics (43)
Diversity, equity & inclusion (4)
Drug discovery (6)
Drug pricing (4)
Drug shortages (1)
Duchenne muscular dystrophy (11)
Earnings (769)
Editorial (8)
Employer branding (8)
Employer resources (12)
Events (874)
Executive appointments (45)
FDA (270)
Friedreich's ataxia (4)
Frontotemporal dementia (5)
Funding (17)
Gene editing (2)
Gene therapy (9)
GLP-1 (41)
Government (74)
Guidances (8)
Healthcare (113)
Huntington's disease (4)
IgA nephropathy (5)
Immunology and inflammation (15)
Immuno-oncology (1)
Indications (1)
Infectious disease (45)
Inflammatory bowel disease (2)
Inflation Reduction Act (1)
Interviews (1)
IPO (132)
Job creations (144)
Job search strategy (23)
JPM (11)
Labor market (2)
Layoffs (33)
Leadership (1)
Legal (92)
Lung cancer (4)
Lymphoma (2)
Machine learning (1)
Management (1)
Manufacturing (13)
MASH (2)
Medical device (20)
Medtech (21)
Mergers & acquisitions (334)
Metabolic disorders (18)
Multiple sclerosis (10)
Neurodegenerative disease (55)
Neuropsychiatric disorders (10)
Neuroscience (437)
Neurotech (1)
NextGen: Class of 2026 (125)
Non-profit (40)
Obesity (16)
Opinion (32)
Pain (3)
Pancreatic cancer (1)
Parkinson's disease (6)
Partnered (1)
Patents (3)
Patient recruitment (2)
People (1611)
Pharmaceutical (1)
Phase 1 (313)
Phase 2 (503)
Phase 3 (625)
Pipeline (59)
Policy (13)
Postmarket research (79)
Preclinical (94)
Prostate cancer (1)
Psychedelics (2)
Rare diseases (28)
Real estate (91)
Recruiting (3)
Regulatory (378)
Research institute (31)
RSV (1)
Schizophrenia (5)
Series A (5)
Series B (2)
Sickle cell disease (1)
Special edition (3)
Spinal muscular atrophy (72)
Startups (109)
Tariffs (3)
The Weekly (17)
Vaccines (8)
Venture capital (1)
Weight loss (7)
Women's health (1)
Date
Last 7 days (3)
Last 30 days (26)
Last 365 days (371)
2026 (35)
2025 (389)
2024 (405)
2023 (455)
2022 (670)
2021 (685)
2020 (584)
2019 (474)
2018 (396)
2017 (533)
2016 (549)
2015 (672)
2014 (340)
2013 (262)
2012 (202)
2011 (197)
2010 (182)
Location
Africa (32)
Alabama (1)
Asia (624)
Australia (53)
California (73)
Canada (38)
China (18)
Colorado (1)
Connecticut (4)
Delaware (1)
Europe (1148)
Florida (6)
Georgia (1)
Illinois (5)
India (1)
Indiana (1)
Japan (27)
Kentucky (1)
Maine (1)
Maryland (7)
Massachusetts (194)
Michigan (1)
Mississippi (1)
Missouri (1)
Nevada (1)
New Hampshire (4)
New Jersey (16)
New York (25)
North Carolina (8)
Northern California (39)
Ohio (3)
Oregon (1)
Pennsylvania (4)
Rhode Island (1)
South America (34)
Southern California (17)
Tennessee (1)
Texas (6)
United States (353)
Utah (1)
Virginia (3)
Washington State (15)
West Virginia (1)
Wisconsin (1)
8,013 Results for "biogenes".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Earnings
Biogen’s ‘Bridge To Growth’ Cuts Through a Stacked Phase 3 Pipeline
With Biogen’s multiple sclerosis portfolio facing more generic pressure than ever, the company is eyeing a busy late-stage pipeline and hunting for deals to build its return to growth.
February 6, 2026
·
2 min read
·
Annalee Armstrong
Alzheimer’s disease
Biogen’s Leqembi Rises After Novo GLP-1 Fails in Alzheimer’s
Analysts agree that the failure of Novo Nordisk’s semaglutide to reduce Alzheimer’s disease progression removes a “modest” or “perceived” overhang on Biogen and the anti-amyloid antibody class in general, clearing the way for increased uptake of Leqembi and Eli Lilly’s Kisunla.
November 24, 2025
·
3 min read
·
Heather McKenzie
Neurodegenerative disease
JPM26: With Leqembi Launched, Biogen Looks To Expand Alzheimer’s Presence
Three years after the accelerated approval of its anti-amyloid Alzheimer’s therapy, Biogen—neck and neck in the market with Eli Lilly and its Kisunla offering—is focused on a near-term FDA decision for a subcutaneous induction dose of Leqembi, a presymptomatic readout in 2028 and a clutch of next-generation candidates.
January 14, 2026
·
5 min read
·
Heather McKenzie
Layoffs
Biogen Shuffles 20 Staff After Ending AAV Work
The AAV pullback comes amid Biogen’s aggressive cost-cutting campaign, which put some 1,000 jobs on the chopping block with the goal of generating $1 billion in savings by 2025.
September 29, 2025
·
2 min read
·
Tristan Manalac
Immunology and inflammation
Biogen Grows Immunology Pipeline With Vanqua’s Anti-Inflammatory Molecule
The $70 million upfront deal adds to a portfolio of drugs Biogen has been growing in various immunological conditions since 2024.
October 24, 2025
·
2 min read
·
Dan Samorodnitsky
Immunology and inflammation
Lupus Reveal Gives Investors a Peek at Biogen’s ‘Underappreciated’ Pipeline
With two late-stage programs set to read out in the next 48 months, Biogen is translating its wealth of experience in multiple sclerosis to lupus—developing a pipeline BMO Capital Markets analysts called “thoughtful.”
September 9, 2025
·
4 min read
·
Heather McKenzie
Earnings
As Biogen Nears Presymptomatic Alzheimer’s Readout for Leqembi, Can Doctors Be Convinced?
To expand the population for the anti-amyloid Alzheimer’s drugs, Lilly and Biogen are testing presymptomatic patients. Will doctors be open to this paradigm-shifting change?
October 30, 2025
·
2 min read
·
Annalee Armstrong
Earnings
Biogen’s Leqembi Push Getting Easier as CEO Eyes Early-Stage Pipeline Restock
Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter earnings call. The partnered Alzheimer’s drug Leqembi saw sales climb 20% for the period.
July 31, 2025
·
4 min read
·
Annalee Armstrong
Press Releases
Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options
January 29, 2026
·
12 min read
Autoimmune disease
Biogen Seeks To Stand Out in Lupus With New Anti-CD40L Data
Phase III data for dapirolizumab pegol presented at the 2025 conference of the American College of Rheumatology showed quality-of-life benefits in systemic lupus erythematosus that could see Biogen go head-to-head with GSK and AstraZeneca in a blockbuster space.
October 28, 2025
·
2 min read
·
Tristan Manalac
1 of 802
Next
